Vaxcyte, Inc. 4

President and CFO Andrew Guggenhime exercised 10,000 options and sold 10,000 Vaxcyte, Inc. (PCVX) common shares for roughly $538K under a Rule 10b5-1 plan.

On August 3, 2026, Vaxcyte, Inc. President and CFO Andrew Guggenhime exercised 10,000 stock options at $5.35 per share and immediately sold the 10,000 resulting common shares in two market sales totaling 6,956 shares at a weighted-average price of $53.761 and 3,044 shares at a weighted-average price of $54.178, all pursuant to a pre-arranged Rule 10b5-1 trading plan. The option exercise generated shares at a low strike price and the subsequent sales realized proceeds of roughly $538,000 while retaining a substantial direct ownership position of 105,176 common shares (excluding 61,850 indirectly held shares via ALG 2025 GRAT HOLDINGS LLC) and 10,000 additional option shares. The filing notes that the reported sales are disclosed in weighted-average form over defined price ranges and that certain shares are held indirectly through a grantor retained annuity trust for which the reporting person serves as annuitant and trustee.

Filing Facts

CIK

1649094

Ticker

PCVX

Form

4

Source Type

fda

Accession

0001230724-26-000014

Alert Tier

6